Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 4Active not recruiting 3Terminated 2Unknown 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Dermatologic 2Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 226Lung Neoplasms 78Neoplasms 37Mesothelioma 23Mesothelioma, Malignant 21Neoplasm Metastasis 20Breast Neoplasms 18Adenocarcinoma of Lung 18Head and Neck Neoplasms 13Colorectal Neoplasms 13Ovarian Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma 8Uterine Cervical Neoplasms 6Non-Squamous Non-Small Cell Lung Cancer 6Adenocarcinoma, Bronchiolo-Alveolar 6Adenocarcinoma 6Unspecified Adult Solid Tumor, Protocol Specific 5Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Meningeal Carcinomatosis 5Brain Neoplasms 5Urinary Bladder Neoplasms 4Small Cell Lung Carcinoma 4Recurrence 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Laryngeal Diseases 4Endometrial Neoplasms 4

Interventions

pembrolizumab 25Gemcitabine 21Nivolumab 17Cisplatin 17atezolizumab 14Carboplatin 11avelumab 9vinflunine 7Ipilimumab 7Paclitaxel 6Docetaxel 5enfortumab vedotin 4cabazitaxel 4Pemetrexed 4Mitomycin 4cabozantinib 3Taxes 3Rogaratinib 3Magnetic Resonance Spectroscopy 3Injections 3Albumin-Bound Paclitaxel 3tremelimumab 2sacituzumab govitecan 2pemigatinib 2niraparib 2lenvatinib 2bempegaldesleukin 2apatorsen 2XRP6258 2Vitamin D 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Carcinoma, Transitional Cell × Pemetrexed × Clear all
NCT04452214 2023-07-14

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

Cantargia AB

Phase 1 Completed
19 enrolled
DermatologicGenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma

NCT02983045 2023-03-13

PIVOT-02

Nektar Therapeutics

Phase 1/2 Completed
557 enrolled 22 charts
BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01490437 2014-09-25

PECULIAR

Asan Medical Center

Phase 2 Completed
42 enrolled
Genitourinary

Carcinoma, Transitional Cell

NCT00101842 2006-08-29

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

Eli Lilly and Company

Phase 1/2 Completed
61 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡